Molecular Genetics and Genomics

American Molecular Laboratories (AML) offers a full suite of genetic and genomic assays:
  • Genotyping Assays: Somatic and Germline
  • Targeted sequencing from FFPE tissue samples

Targeted Cancer Mutation Detection:

AML offers Targeted NGS Panels and organ-specific custom NGS panels. Our targeted NGS cancer panel (Clinical Test menu: AmOnco88TM Comprehensive Cancer) provides a comprehensive analysis of well-characterized cancer genes that includes:
  • Sequencing of the entire coding region
  • Analysis of rearrangements
  • Microsatellite Instability Analysis (MSI)
  • Custom Bioinformatics Analysis

Figure Legend.  Genetic alterations in the HER/PI3K pathway contribute to aberrant signaling and cell proliferation.  Schematic representation of the HER/PI3K pathway. The majority of tumors (95%) stain positive for phosphorylated S6, a surrogate marker for PI3K/mTOR activity.

Whole Exome Sequencing:

Whole exome sequencing with coverage of over 20,000 genes with a detailed bioinformatics analysis that includes:
  • Sequence Mapping
  • Somatic Mutation Analysis
  • Copy Number Analysis
  • Germline Variant Analysis
  • Functional data analysis and data summary that provides biologic pathway analysis and clinical information
  • Neoantigen Prediction (optional)

Gene Expression Analysis:

AML offers a wide variety of innovative gene expression analysis solutions that can be customized to the requirements of your clinical and translational research programs. AML’s technology platforms allow for the qualitative and quantitative gene expression analysis. AML’s RNA-based technologies include:
  • Whole Transcriptome RNA-Seq
  • Targeted RNA Expression Panels (Fixed and Custom)

  • Quantitative real-time PCR (qRT-PCR)
  • Bioinformatics Analysis (Annotation, pathway analysis, and differential expression analysis)